Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center have signed memorandum of understanding (MoU) to explore a collaboration focused on research, development and commercialization of drugs in Russia and other countries.
Subscribe to our email newsletter
The two companies intend to develop certain compounds through technology transfer and out-licensing deals with venture funding from Pfizer’s pipeline.
Under the terms of the MoU, the two companies can further collaborate with other partners, including the the Skolkovo Foundation, Moscow Institute of Physics and Technology, and other members of the Russian Biopharmaceutical Cluster ‘Northern,’ created under the Federal Target Program of the Ministry of Industry and Trade of the Russian Federation.
In addition, the companies can establish a shared-risk platform for several Pfizer R&D programs designed to achieve clinical candidates and proof of concept in the clinic.